On October 6, 2026 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported the presentation of new clinical research at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place from October 23-27 in Madrid, Spain. Highlights from the company’s 10 abstracts will cover new data and analyses from trials in cutaneous squamous cell carcinoma (CSCC), non-small cell lung cancer (NSCLC), ovarian cancer, melanoma and cancer-associated thrombosis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At ESMO (Free ESMO Whitepaper), we look forward to sharing data across a range of conditions reflecting the breadth of our research," said Israel Lowy, M.D., Ph.D., Clinical Development Unit Head, Oncology, at Regeneron. "For the first time, we’re showcasing how our work extends beyond the treatment of cancer itself, and addresses some of the complex challenges patients face as a result of their disease. Together, these data reflect our broader commitment to advancing comprehensive cancer care for patients."

Highlights include:

Adjuvant treatment with Libtayo in adults with CSCC with high risk of recurrence after surgery and radiation: Late-breaking overall survival (OS) data at approximately 3.5 years follow-up from the C-POST Phase 3 trial will provide further evidence supporting Libtayo as the standard of care in this indication.
Neoadjuvant treatment with Libtayo in stage II-IV CSCC: Data include the final analysis of Phase 2 results, which represent the most mature data set in patients treated with Libtayo prior to surgery.
Factor XI antibodies (cenvacibart and amrecibart) as a potential approach to reducing thrombosis in patients with cancer: Data include a Phase 2 sub-analysis and modeling in catheter-related VTE, plus an update on the Phase 3 ROXI-CAT-II trial.

The full list of Regeneron presentations at ESMO (Free ESMO Whitepaper) are as follows: 

Abstract Title Abstract Presenter Session Date/Time (CET)
Skin Cancer
C-POST Phase 3 trial of adjuvant cemiplimab vs. placebo for high-risk CSCC: OS update at approximately 3.5 years’ median follow-up LBA: 59
Danny Rischin Sunday
October 25,
10:15-11:45
A Phase 2 study of neoadjuvant cemiplimab for Stage II–IV CSCC: final analysis Poster presentation: 2490P Neil D. Gross Saturday
October 24,
12:00-12:45
Long-term Overall Survival (OS) with Fianlimab (FIAN) plus Cemiplimab (Cemi) in Advanced Melanoma (aMel): Survival Follow-up of a Phase 1 Study Poster presentation: 2091P Omid Hamid Saturday
October 24,
12:00-12:45
Lung Cancer
Impact of objective response on PROs in patients receiving cemiplimab + chemotherapy vs. placebo + chemotherapy for aNSCLC: EMPOWER-Lung 3 Part 2 Poster presentation: 2714P Konstantin Penkov Monday
October 26,
12:00-12:45
CEMI-LUNG, a European-based observational study to assess cemiplimab real world effectiveness and safety in patients with advanced non-small cell lung cancer Poster presentation: 2580P Jesus Corral Jaime Monday
October 26,
12:00-12:45
Ovarian Cancer
Circulating tumor DNA (ctDNA), cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) associate with survival outcomes in patients with platinum-resistant ovarian cancer treated with ubamatamab Poster presentation: 1957P Jung-Yun Lee Saturday
October 24,
12:00-12:45
A Phase 1/2 study of REGN5668 (ubamatamab) (mucin 16 [MUC16] × cluster of differentiation [CD]28 costimulatory bispecific antibody), in combination with other targeted therapies, in patients with recurrent ovarian cancer or endometrial cancer: Trial in progress update ePoster presentation: 1445eTiP Roisin E. O’Cearbhaill N/A
Thrombosis (cenvacibart [REGN7508] and amrecibart [REGN9933])
Phase 3 trial-in-progress evaluating cenvacibart for the treatment and secondary prevention of venous thromboembolism (VTE) in participants with solid and hematologic cancers (ROXI-CAT-II) ePoster presentation: 1534eTiP Andrés J. Muñoz N/A
Sub-analysis of a Phase 2 study investigating amrecibart and cenvacibart for the prevention of contact-mediated VTE in participants with active cancer undergoing peripherally inserted central catheter (PICC) placement (ROXI-CATH) Poster presentation: 1468P Jeffrey I. Zwicker Monday
October 26,
12:00-12:45
Population pharmacokinetic/pharmacodynamic modeling of REGN7508Cat in patients with a PICC from ROXI-CATH who have active cancer supports maximal Factor XI pathway inhibition Poster presentation: 3968P Jeffrey I. Zwicker Saturday
October 24,
12:00-12:45

The potential uses of neoadjuvant Libtayo in CSCC, ubamatamab, cenvacibart and amrecibart described above are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.

(Press release, Regeneron, OCT 6, 2026, View Source [SID1234673246])

On October 6, 2026 Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, reported an approximately $5.6 million private investment in public equity (PIPE) financing through the issuance of common stock, without any accompanying investor warrants or convertible securities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The financing includes an additional $1.0 million investment from billionaire entrepreneur and existing significant shareholder John Paul DeJoria, co-founder of John Paul Mitchell Systems and Patrón Spirits. Other existing shareholders and new investors also participated in the financing.

DeJoria most recently reported beneficial ownership of approximately 3.55 million shares, representing approximately 5.0% of Telomir’s outstanding common stock. His additional $1.0 million investment further increases his investment in Telomir as the Company advances its lead program into clinical development.

"I have always looked for opportunities that can do the greatest good for the greatest number of people, and that is part of what attracted me to Telomir," said John Paul DeJoria. "Cancer continues to take an enormous toll on patients and families, and there remains a need for new approaches that can potentially improve the way we treat this disease. Telomir is pursuing a different scientific approach, and with the Company now moving into human clinical trials, I am pleased to increase my investment and support the team as they work to determine what Telomir-Zn may be able to do for patients."

Alexander Capital, L.P. acted as placement agent for the financing. The Company expects to receive aggregate gross proceeds of approximately $5.6 million, before deducting placement agent fees and other offering expenses.

Financing Terms

Under the terms of the financing, Telomir issued 4,843,300 shares of common stock at a purchase price of $1.16 per share, representing a 5% discount to the applicable 10-day volume-weighted average price (VWAP). The financing resulted in aggregate gross proceeds to the Company of approximately $5.6 million, before deducting placement agent fees and other offering expenses.

Investors in the financing purchased common stock at a fixed price, with no accompanying investor warrants, convertible securities, or variable-price or reset features.

The securities were issued in a private placement. Telomir has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares issued in the financing, subject to the terms of the Registration Rights Agreement.

The Company intends to use the net proceeds primarily to support the clinical development of Telomir-Zn, including its Phase 1/2 clinical program in advanced or metastatic triple-negative breast cancer (TNBC), as well as for working capital and general corporate purposes.

"We have been very deliberate about how and when we access the capital markets," said Erez Aminov, Chairman and CEO of Telomir. "Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders. As Telomir enters clinical development, our focus is on execution: deploying this capital efficiently to advance Telomir-Zn through its Phase 1/2 clinical program, generate meaningful human data and position the Company strongly for the milestones ahead."

Strengthening Telomir’s Position for Clinical Execution

The financing comes as Telomir advances Telomir-Zn, its lead investigational oral small molecule, into human clinical evaluation. The U.S. Food and Drug Administration has cleared Telomir’s Investigational New Drug (IND) application for Telomir-Zn, enabling the Company to proceed with its first-in-human Phase 1/2 clinical trial in patients with advanced or metastatic TNBC.

TNBC is an aggressive form of breast cancer defined by the absence of three common therapeutic targets, estrogen receptors, progesterone receptors, and HER2, limiting the applicability of many targeted treatments used in other forms of breast cancer. Patients with advanced or metastatic disease continue to face a significant need for additional treatment options.

The multicenter, open-label Phase 1/2 study is designed to move Telomir-Zn from initial human dosing through dose selection and into an efficacy-focused expansion. The Phase 1 portion will evaluate safety, tolerability, and dose selection while also assessing pharmacodynamic biomarkers and preliminary signals of antitumor activity. The Phase 2 expansion is designed to build on those findings with a greater focus on efficacy, providing an initial clinical proof-of-concept assessment of Telomir-Zn in advanced or metastatic TNBC.

A New Epigenetic Approach to Treating Cancer

Telomir-Zn is being developed as a potentially first-in-class oral epigenetic therapy designed to modulate intracellular metal homeostasis, particularly iron and copper, and influence gene-control pathways implicated in cancer. Preclinical studies have demonstrated inhibition of multiple iron-dependent histone demethylases (KDMs), supporting the Company’s hypothesis that Telomir-Zn may help restore more normal epigenetic regulation and potentially reactivate tumor-suppressor pathways that cancer has silenced.

(Press release, Telomir Pharmaceutical, OCT 6, 2026, View Source [SID1234673245])

On October 6, 2026 Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, reported that new preclinical data from its lead oncology program, ERNA-101, have been selected for a Flash Talk presentation at the Next-Generation Cancer Therapeutics meeting, co-hosted by Nature Conferences and The University of Texas MD Anderson Cancer Center.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The meeting will take place October 6–8, 2026, on MD Anderson’s campus in Houston, Texas. The presentation will highlight ERNA-101’s potential to address a fundamental challenge in ovarian cancer: the immunosuppressive tumor microenvironment that can limit effective antitumor immune responses. In preclinical models of high-grade serous ovarian cancer, ERNA-101 promoted immune cell recruitment and was associated with significant tumor regression and enhanced survival. When combined with PD-1 checkpoint blockade, ERNA-101 demonstrated enhanced antitumor activity, including complete tumor control and durable responses in the majority of treated animals.

"Selection for presentation at a Nature Conferences meeting co-hosted by MD Anderson Cancer Center highlights the strength of our preclinical findings for ERNA-101, and we look forward to engaging with researchers and oncology leaders focused on advancing the next generation of cancer therapies," said Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics. "Our data demonstrate the potential of our allogeneic, off-the-shelf approach to deliver immune-activating cytokines to the tumor microenvironment, recruit key immune cells and enhance the activity of checkpoint blockade. We believe these findings provide a strong scientific foundation for advancing ERNA-101 toward the clinic and investigating its potential to address the significant unmet need in ovarian cancer."

Presentation Details

Title: IL7-IL15-iMSCs (ERNA-101): Allogeneic, Off-the-Shelf, Next-Generation Immune-Enhancing Cell Therapy of Cancer
Session: Flash Talk Date: Tuesday, October 6, 2026
Location: The University of Texas MD Anderson Cancer Center, Houston, Texas

The presentation will feature preclinical findings demonstrating ERNA-101’s ability to recruit T cells and proinflammatory macrophages and promote an immune-active tumor microenvironment in models of high-grade serous ovarian cancer. In combination with PD-1 checkpoint blockade, ERNA-101 achieved complete tumor control and durable responses in the majority of treated animals, with the findings reproduced in a larger cohort. Biodistribution studies also showed localization of ERNA-101 to the tumor microenvironment, with no detectable signal in the peritoneal wash, serum or other organs evaluated.

Co-hosted by Nature Conferences and MD Anderson Cancer Center, the Next-Generation Cancer Therapeutics meeting will bring together researchers from academia, biotechnology and the pharmaceutical industry to discuss emerging approaches to cancer treatment, including next-generation biologics, immunotherapies, targeted therapies and novel therapeutic platforms. For more information, please visit the conference website.

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

About ERNA-101

ERNA-101 is Ernexa’s lead oncology program, comprising allogeneic, off-the-shelf, induced pluripotent stem cell-derived mesenchymal stromal cells (iMSCs) engineered to express IL-7 and IL-15 as a single fusion protein (IL-7_IL-15-fusokine). ERNA-101 is designed to deliver an immune-activating cytokine payload to the tumor microenvironment, promote antitumor immune responses and potentially enhance the activity of checkpoint blockade. Ernexa is advancing ERNA-101 toward clinical development for ovarian cancer.

(Press release, Ernexa Therapeutics, OCT 6, 2026, View Source [SID1234673244])

On October 6, 2026 Sensible Biotechnologies ("Sensible"), a biotechnology company developing a first-of-its-kind platform for naturally modified mRNA medicines, reported that it has secured $47 million in financing to advance and scale its integrated mRNA technology. The financing includes a Series A and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Series A included participation from new investors OTB Ventures and In-Q-Tel, alongside existing investors Recode Ventures, Isomer Capital, Y Combinator, Backed VC, Kaya VC, Civilization Ventures and BlueYard Capital, as well as the family office of Christoph Huber, Co-Founder of BioNTech, Tim Garnett, former Chief Medical Officer of Eli Lilly, and other individual investors.

The funding will support the development and scale-up of Sensible’s VECTOR (Versatile Engine for Cell-based Therapeutic Optimisation of RNA) platform, expansion of its AI-enabled mRNA design and automated high-throughput screening capabilities, and development of clinical-grade manufacturing capabilities.

"mRNA transformed vaccines, but we believe its greatest potential lies in therapeutics," said Miroslav Gasparek, Chief Executive Officer and Co-Founder of Sensible Biotechnologies. "The field still relies largely on synthetic manufacturing technology developed more than 40 years ago. We are taking a fundamentally different approach, using living cells to produce naturally modified mRNA while reducing the cost and supply-chain constraints of conventional production. With this financing, we can scale our platform and expand mRNA into therapeutic applications requiring high or repeated dosing that have historically been limited by cost."

While mRNA has transformed vaccines, its broader therapeutic potential remains largely unrealized, due in part to the limitations of synthetic production. Sensible is taking a different approach by making mRNA in living cells. Sensible’s VECTOR platform integrates computational and AI-enabled sequence optimization, high-throughput screening and proprietary engineered eukaryotic cells to design and manufacture naturally modified mRNA. The Company’s PromPT technology captures and protects mRNA inside cells before it is purified for therapeutic use.

By harnessing the natural machinery of living cells, Sensible’s platform is designed to produce naturally modified mRNA with reduced immunogenicity and high protein expression while avoiding double-stranded RNA (dsRNA) contamination, a key source of unwanted immune activation. In external evaluations, Sensible’s platform demonstrated the ability to produce cell-made mRNA with no detectable dsRNA contamination, reduced cytokine activation and higher protein expression compared with synthetic mRNA in human immune-cell assays.

Integrating design and manufacturing within a single platform also has the potential to reduce the complexity and supply-chain constraints of conventional mRNA production. By using engineered living cells, Sensible aims to reduce reliance on specialized raw materials and manufacturing inputs, enabling more scalable production and expanding mRNA into therapeutic applications requiring higher or repeated dosing.

In connection with the financing, Dr. Vishal Gulati, FMedSci, Managing Partner at Recode Ventures, and Joel Schoppig, Partner at Oxford Science Enterprises, will join Sensible’s Board of Directors alongside Miroslav Gasparek, Chief Executive Officer and Co-Founder, and Dr. Marian Kupculak, Chief Scientific Officer and Co-Founder.

"The promise of computational drug design depends on connecting it to biology and the practical work of making a medicine. How mRNA is made can shape how it behaves, so manufacturing matters from the very start of developing a treatment. Sensible brings design and cell-based production together, giving the team an opportunity to improve both the performance of mRNA and the economics of making it," said Joel Schoppig, Partner at Oxford Science Enterprises and Board Member at Sensible. "We led this round because we believe in the team’s ability to build a company that helps pharmaceutical partners develop a broader range of mRNA medicines. With this investment, Sensible can advance toward clinical-grade production and expand the pharmaceutical partnerships that will drive its commercial growth."

"The next wave of mRNA medicines reaches far beyond vaccines: in vivo CAR-T, gene editing, and cancer immunotherapy. Yet much of that promise is capped by the limits of today’s mRNA design and manufacturing. Sensible has rebuilt the process from first principles. Its cell-based platform brings design, optimisation and manufacturing into a single loop, producing purer, low-immunogenicity mRNA at industrial scale. That is why we backed Sensible from its earliest round." said Dr Vishal Gulati, FMedSci, Managing Partner at Recode Ventures and Board Member at Sensible.

"Sensible represents exactly that kind of scientific innovation that can help shape the future of medicine," said Kamil Šaško, Minister of Health of the Slovak Republic. "Its work to develop a new generation of mRNA technologies reflects the strength of biotechnology innovation emerging from Slovakia and Europe. We are proud to support Sensible as it advances pioneering science with the potential to enable better medicines, expand the possibilities of mRNA therapeutics, and ultimately improve the lives of patients around the world. Such support is an investment Europe truly needs not only in scientific progress, but in our ability to lead the next generation of biotechnology and healthcare innovation."

The Company has established collaborations to support the validation and scale-up of its technology, such as a strategic partnership with Sartorius to scale its cell-based platform toward clinical-grade mRNA manufacturing and additional partnerships with leading technology companies. Sensible’s cell-based circular RNA manufacturing technology has also been published in Nature Biotechnology and Cell Chemical Biology.

(Press release, Sensible Biotechnologies, OCT 6, 2026, View Source [SID1234673243])

On October 6, 2026 Agendia, Inc., a leader in precision oncology for breast cancer, reported that it will present new research during a podium presentation on the development of an artificial intelligence (AI)-driven digital pathology approach for MammaPrintⓇ at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, which takes place October 23 to 27, 2026, in Madrid. The company will also present two additional posters at ESMO (Free ESMO Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AI-driven digital pathology approaches are rapidly developing to expand access to genomic testing globally. Agendia’s first presentation, submitted as a late-breaking abstract, focuses on the development and validation of an AI-driven MammaPrint approach based on the analysis of routine whole slide images of breast cancer tissue.

The following are details of the late-breaking abstract to be presented on the podium:

PODIUM PRESENTATION: AI Driven Digital Pathology for the 70 Gene Recurrence Signature: Development and Validation in Early Stage Breast Cancer

Presenter: Laura van ‘t Veer, PhD, Co-founder and Chief Research Officer, Agendia
Session: AI and digital health
Abstract Number: LBA20
Date / Time: Saturday, October 24, 2026 | 14:45 to 16:15 CEST
Location: Bilbao Auditorium, Hall 3
Agendia will also present two additional posters that draw on the ongoing real-world FLEX Study, demonstrating how a large, real-world breast cancer research platform can support investigations across biomarkers, inherited mutations and genomic tumor biology. The research will highlight the relationship between genomic risk and Ki67 and the correlation between germline BRCA1 and BRCA2 mutations with gene expression profiling.

"Germline BRCA1 and BRCA2 mutations are associated with distinct breast cancer phenotypes, but their association with gene expression-based subtypes has not been well-studied. Ki67 is a biomarker whose utility is limited by variability between laboratories and by the lack of consensus on meaningful levels of expression," said William Audeh, M.D., M.S., Chief Medical Officer at Agendia. "Both studies we are bringing to ESMO (Free ESMO Whitepaper) 2026 to illustrate how genomic risk classification correlates with these biomarkers in a real-world population. The FLEX Study has allowed questions like these to be answerable through the analysis of large scale real-world evidence, and we look forward to sharing the complete findings in Madrid following their scheduled presentations."

The following are details of the two additional abstracts that have been accepted as poster presentations:

70-Gene Signature Provides Prognostic Value Beyond Ki67 in HR+HER2- Early Breast Cancer (EBC)
Presenter: Michael Gnant, MD, Full Professor of Surgery, Medical University of Vienna
Session: Breast cancer, early stage
Presentation Number: 578P
Date / Time: Saturday, October 24, 2026 | 12:00 to 12:45 CEST
Impact of Germline BRCA1 and BRCA2 Mutations on 70-Gene Signature Risk for Patients Enrolled in the FLEX Study
Presenter: Amir Sonnenblick, MD, PhD, Associate Professor, Tel Aviv University
Session: Breast cancer, early stage
Abstract Number: 564P
Date / Time: Saturday, October 24, 2026 | 12:00 to 12:45 CEST
About the FLEX Study
The MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles (FLEX) Study (NCT03053193) is a large-scale, prospective, observational breast cancer study that links whole transcriptome profiling, including MammaPrint and BluePrint, with complete clinical data. The largest and most diverse early-stage breast cancer cohort, the FLEX Study has enrolled over 25,000 patients globally, including 2,235 self-reported Black/African American, 2,125 Latin American/Hispanic, and 602 Asian American/Pacific Islander patients. FLEX also represents one of the largest cohorts of invasive lobular carcinoma (ILC), with 2,981 ILC and 853 mixed ILC/ductal histology tumors. FLEX supports collaborative substudies designed to expand our understanding of breast cancer biology and inform more personalized, equitable care.

(Press release, Agendia, OCT 6, 2026, View Source [SID1234673242])